Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT) Dziadziuszko, R., Ahn, M., Kelly, K. A., Popat, S., Wakelee, H., Baird, A., Rooney, I. A., Afshari, M., Yao, E. S., Zhang, Z., Kuriki, H., Patil, N. S., Wen, X., Bradley, J. D. ELSEVIER. 2021: S947-S948
View details for DOI 10.1016/j.annonc.2021.08.1794
View details for Web of Science ID 000700527702207